Gilead Sciences Shares Sold by Tritonpoint Wealth

Institutional investor reduces stake in biopharmaceutical company

Apr. 5, 2026 at 11:58am

Got story updates? Submit your updates here. ›

Tritonpoint Wealth LLC, a major institutional investor, has reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 66.3% during the fourth quarter, according to a recent SEC filing. The firm now owns 2,382 shares of the biopharmaceutical company's stock, down from 7,061 shares previously.

Why it matters

Gilead Sciences is a prominent biopharmaceutical company known for its antiviral therapies, particularly in the areas of HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential shifts in the broader healthcare sector.

The details

According to the SEC filing, Tritonpoint Wealth LLC sold 4,679 shares of Gilead Sciences during the fourth quarter, reducing its total holdings to 2,382 shares. The firm's stake in the company is now valued at $292,000, down from $867,000 at the end of the previous quarter. The sale represents a 66.3% reduction in Tritonpoint's position in Gilead Sciences.

  • The SEC filing covers Tritonpoint Wealth LLC's holdings as of the end of the fourth quarter of 2025.

The players

Tritonpoint Wealth LLC

A major institutional investor that has reduced its stake in Gilead Sciences, Inc.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Tritonpoint Wealth's holdings in Gilead Sciences could signal a shift in market sentiment towards the biopharmaceutical company, though further analysis of broader industry trends and other institutional investors' actions would be needed to draw more definitive conclusions.